JP2024029009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024029009A5 JP2024029009A5 JP2023212944A JP2023212944A JP2024029009A5 JP 2024029009 A5 JP2024029009 A5 JP 2024029009A5 JP 2023212944 A JP2023212944 A JP 2023212944A JP 2023212944 A JP2023212944 A JP 2023212944A JP 2024029009 A5 JP2024029009 A5 JP 2024029009A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- small cell
- lung cancer
- mdm2 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 18
- 229940083338 MDM2 inhibitor Drugs 0.000 claims 14
- 239000012819 MDM2-Inhibitor Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229940124060 PD-1 antagonist Drugs 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165111.0 | 2017-04-05 | ||
| EP17165111 | 2017-04-05 | ||
| EP17197930.5 | 2017-10-24 | ||
| EP17197930 | 2017-10-24 | ||
| PCT/EP2018/058562 WO2018185135A1 (en) | 2017-04-05 | 2018-04-04 | Anticancer combination therapy |
| JP2019554792A JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Division JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024029009A JP2024029009A (ja) | 2024-03-05 |
| JP2024029009A5 true JP2024029009A5 (enExample) | 2024-03-25 |
Family
ID=61899297
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Ceased JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
| JP2023212944A Pending JP2024029009A (ja) | 2017-04-05 | 2023-12-18 | 抗がん併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554792A Ceased JP2020516604A (ja) | 2017-04-05 | 2018-04-04 | 抗がん併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200101079A1 (enExample) |
| EP (2) | EP3606556A1 (enExample) |
| JP (2) | JP2020516604A (enExample) |
| KR (2) | KR20240090927A (enExample) |
| CN (2) | CN114949228A (enExample) |
| AU (1) | AU2018248586A1 (enExample) |
| BR (1) | BR112019021032A2 (enExample) |
| CA (1) | CA3057558A1 (enExample) |
| CL (2) | CL2019002800A1 (enExample) |
| MX (1) | MX2019011945A (enExample) |
| PH (1) | PH12019502291A1 (enExample) |
| WO (1) | WO2018185135A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| CN114773481B (zh) | 2015-10-02 | 2025-04-29 | 豪夫迈·罗氏有限公司 | 对pd1和tim3特异性的双特异性抗体 |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| FI3606955T3 (fi) | 2017-04-05 | 2025-01-08 | Hoffmann La Roche | Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita |
| KR20200134253A (ko) * | 2018-03-20 | 2020-12-01 | 노파르티스 아게 | 약제학적 병용물 |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2020030016A1 (en) * | 2018-08-08 | 2020-02-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of immunotherapies with mdm2 inhibitors |
| CA3114299A1 (en) * | 2018-11-01 | 2020-05-07 | Alpha Tau Medical Ltd. | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen |
| US20220040166A1 (en) * | 2018-12-11 | 2022-02-10 | Kartos Therapeutics | Methods and Compositions of Treating an Ophthalmic Condition |
| IL310121A (en) | 2021-08-09 | 2024-03-01 | Boehringer Ingelheim Int | A preparation for oral administration that includes an MDM2-antagonist for the treatment of cancer |
| CN115089585A (zh) * | 2022-08-05 | 2022-09-23 | 中国科学院大学宁波华美医院 | Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用 |
| TW202440585A (zh) * | 2022-12-22 | 2024-10-16 | 德商百靈佳殷格翰國際股份有限公司 | MDM2-p53抑制劑之晶型及醫藥組合物 |
| WO2024238404A2 (en) * | 2023-05-12 | 2024-11-21 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US7884107B2 (en) | 2006-06-30 | 2011-02-08 | Merck | Substituted piperidines that increase P53 activity and the uses thereof |
| EA200901212A1 (ru) | 2007-03-29 | 2010-04-30 | Новартис Аг | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR073578A1 (es) | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| EP3192811A1 (en) * | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
| EP3508502B1 (en) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| JP6577958B2 (ja) | 2014-04-11 | 2019-09-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用 |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| SI3183254T1 (sl) * | 2014-08-21 | 2019-08-30 | Boehringer Ingelheim International Gmbh | Nove spiro(3H-indol-3,2'pirolidin)-2(1H)-onske spojine in derivati kot inhibitorji MDM2-P53 |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| US20170340733A1 (en) * | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| PL3317301T3 (pl) * | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
| AR106314A1 (es) | 2015-10-09 | 2018-01-03 | Boehringer Ingelheim Int | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 |
| MX393609B (es) * | 2016-05-18 | 2025-03-24 | Boehringer Ingelheim Int | Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer |
| WO2019063802A1 (en) * | 2017-09-29 | 2019-04-04 | Boehringer Ingelheim International Gmbh | ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1 |
-
2018
- 2018-04-04 EP EP18715685.6A patent/EP3606556A1/en not_active Withdrawn
- 2018-04-04 AU AU2018248586A patent/AU2018248586A1/en not_active Abandoned
- 2018-04-04 JP JP2019554792A patent/JP2020516604A/ja not_active Ceased
- 2018-04-04 BR BR112019021032A patent/BR112019021032A2/pt unknown
- 2018-04-04 CN CN202210548008.6A patent/CN114949228A/zh active Pending
- 2018-04-04 KR KR1020247017327A patent/KR20240090927A/ko active Pending
- 2018-04-04 MX MX2019011945A patent/MX2019011945A/es unknown
- 2018-04-04 CN CN201880023850.XA patent/CN110505884B/zh active Active
- 2018-04-04 CA CA3057558A patent/CA3057558A1/en active Pending
- 2018-04-04 EP EP24157330.2A patent/EP4368200A3/en not_active Withdrawn
- 2018-04-04 KR KR1020197032689A patent/KR20190132687A/ko not_active Ceased
- 2018-04-04 WO PCT/EP2018/058562 patent/WO2018185135A1/en not_active Ceased
- 2018-04-04 US US16/500,572 patent/US20200101079A1/en not_active Abandoned
-
2019
- 2019-10-01 CL CL2019002800A patent/CL2019002800A1/es unknown
- 2019-10-04 PH PH12019502291A patent/PH12019502291A1/en unknown
-
2022
- 2022-07-15 US US17/812,735 patent/US20230025452A1/en not_active Abandoned
-
2023
- 2023-10-02 CL CL2023002946A patent/CL2023002946A1/es unknown
- 2023-12-18 JP JP2023212944A patent/JP2024029009A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024029009A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2021155426A5 (enExample) | ||
| JP6761852B2 (ja) | がん治療 | |
| JP2024133474A5 (enExample) | ||
| WO2010081817A1 (en) | Method for treating colorectal cancer | |
| JP2019517549A5 (enExample) | ||
| JP2020502261A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| EA006295B1 (ru) | Применение производных дистамицина для противоопухолевой терапии | |
| RU2004124943A (ru) | Комбинации, включающие эпотилоны и антиметаболиты | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| RU2539394C1 (ru) | Способ лечения стерномедиастинита | |
| JPWO2020030977A5 (enExample) | ||
| JPWO2019226685A5 (enExample) | ||
| JPWO2022260132A5 (enExample) | ||
| CN1302777C (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 | |
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| US20240173323A1 (en) | Combination therapy for cancer treatment | |
| US9757396B2 (en) | Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2 | |
| Eswaran et al. | Concurrent chemoradiation with nano-paclitaxel and carboplatin in locally advanced cervical cancer: A study at quaternary care medical center | |
| JPWO2021262562A5 (enExample) | ||
| CN120202006A (zh) | 卡帕塞替尼和维奈托克的治疗组合 |